Eli Lilly Eyes French Biotech Abivax for Ulcerative Colitis Drug Deal
Pharma giant Eli Lilly considers acquiring French biotech Abivax for its promising ulcerative colitis treatment, expected to launch in 2027.
/ 2 items
Pharma giant Eli Lilly considers acquiring French biotech Abivax for its promising ulcerative colitis treatment, expected to launch in 2027.
Wolfe Research initiates coverage of Abivax with an Outperform rating and $176 price target, citing strong potential for Crohn’s disease success and upcoming 2026 catalyst.